Apr 05,2018

Insulet to Announce First Quarter 2018 Financial Results on May 3, 2018

Insulet Corporation (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the first quarter of 2018 on May 3, 2018 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Apr 09,2018

Tandem Diabetes Care and Movi SpA Announce Agreement for Distribution of Insulin Pump Products in Italy

Tandem Diabetes Care®, Inc., a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into a distribution agreement with Movi SpA to commercialize Tandem’s t:slim X2™ Insulin Pump in Italy.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Apr 09,2018

Nemaura Medical Appoints Bashir Timol Chief Business Officer

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced that Bashir Timol, current Director of Strategy & Corporate Development, has been named Chief Business Officer, effective immediately.

View Analyst & Ambassador Comments
Go to original news
Apr 13,2018

One Drop Direct-to-Consumer Subscriptions Lower A1c by 1.9% in 3 Months

One Drop's direct-to-consumer digital therapeutics solution lowers estimated A1c (eA1c) in people with type 2 diabetes by 1.90% in just 3 months. These findings were published in two peer-reviewed retrospective studies presented at the 39th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine (SBM). The company has released over a dozen peer-reviewed studies on the efficacy of its mobile app and coaching service respectively, but these most recent analyses are the first to examine One Drop’s fully integrated solution.

CLINICAL STUDY

#dtx

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 23,2018

Tandem Diabetes Care Announces Agreements for Distribution of Insulin Pump Products in Australia and New Zealand

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into distribution agreements with Australasian Medical & Scientific Ltd (AMSL) and New Zealand Medical & Scientific Ltd (NZMS) to commercialize Tandem’s t:slim X2™ Insulin Pump in Australia and New Zealand, respectively.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Apr 26,2018

Tandem Diabetes Care Reports First Quarter 2018 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the quarter ended March 31, 2018. Net loss for the first quarter of 2018 was $32.7 million, compared to $23.8 million for the same period of 2017.

View Analyst & Ambassador Comments
Go to original news
Apr 27,2018

BD Names Three Executives to Segment Leadership Roles

BD, a leading global medical technology company, today announced three executive appointments to the positions of segment president. Alberto Mas, 56, has been named president of the Medical Segment for BD, effective May 29, reporting to Tom Polen, president of BD. For the past two years, Mas has held the role of president of the Life Sciences Segment for BD, and prior to that served as president of three major business units including Diagnostic Systems, Biosciences and Medical Surgical Systems (now known as Medication Delivery Solutions).

View Analyst & Ambassador Comments
Go to original news
Apr 30,2018

Tandem Diabetes Care Receives CE Mark for t:slim X2 Insulin Pump

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) today announced receipt of CE mark approval for the t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration. The Company plans to begin commercial sales of the pump in select international markets beginning in the second half of 2018. The Company has been commercializing its touchscreen insulin pumps in the United States since 2012, and received U.S. Food and Drug Administration (FDA) approval of the t:slim X2™ Insulin Pump with Dexcom G5 Mobile CGM integration in August 2017.

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
May 07,2018

Vida Health revamps platform, offers targeted programs for diabetes, behavioral health

San Francisco-based Vida Health announced an update to its digital health coaching platform for enterprises that is specifically designed to target comorbidities, as well as the launch of two separate offerings with a specific focus on diabetes and behavioral health treatment. The first of these announcements is an attempt by the company to offer holistic health coaching that responds to the impact co-present conditions can have on an individual’s health, according to a statement. Meanwhile, the more vertical releases are intended to give enterprise customers the flexibility to purchase employee health support more suited to specific needs.

PRODUCT

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
May 10,2018

Report: Data on diabetes apps' clinical impact scarce, inconsistent

Of the hundreds of diabetes self-management apps currently available, very few have been evaluated with health outcome-focused studies, according to a recent report by the Agency for Healthcare Research and Quality (AHRQ). Among this subset, even fewer have been shown to actually help diabetes patients significantly improve their HbA1c levels.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES